Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08, Zacks reports.

Denali Therapeutics Trading Down 8.2 %

Shares of NASDAQ DNLI traded down $1.36 during trading on Monday, reaching $15.20. The company had a trading volume of 2,262,750 shares, compared to its average volume of 992,887. The stock has a market capitalization of $2.19 billion, a PE ratio of -5.51 and a beta of 1.43. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The stock has a 50-day moving average price of $21.29 and a two-hundred day moving average price of $24.57.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DNLI. Oppenheimer dropped their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday. Baird R W raised Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. The Goldman Sachs Group cut their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. HC Wainwright upped their price objective on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a report on Friday. Finally, William Blair reiterated an "outperform" rating on shares of Denali Therapeutics in a research report on Friday. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.77.

Remove Ads

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 3,080 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the transaction, the director now owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares of the company's stock, valued at $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.